Cytokinetics Wins Health Canada Approval for MYQORZO
Health Canada approved MYQORZO (aficamten) to treat adults with NYHA class II–III obstructive hypertrophic cardiomyopathy, Cytokinetics said. The company said this is its fifth approval, after approvals in the U.S., China, the EU and U.K.
Cytokinetics said Health Canada approved MYQORZO (aficamten) for treating adults with NYHA class II-III obstructive HCM. The approval is the drug’s fifth, following approvals in the U.S., China, the EU and the U.K.